NovalGen is an innovative immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer.

NovalGen is focused on the development of cutting-edge, proprietary treatments for patients with hematologic malignancies and solid tumors by developing therapeutics that treat cancer using our breakthrough technologies in Bispecific antibodies and beyond.

Our strategy

Our mission is to create life-enhancing and curative new treatments for people with cancer.

Our strategy

Our board

Find out more about our team.

Our board

Our history

Headquartered in London, UK, NovalGen was formed in 2019. The company is based on proprietary innovation from UCL, London UK.

Our history

Our values

NovalGen is guided by our core set of values. The culture of NovalGen reflects these values and they help guide our decisions.

Our values